JP7550864B2 - 癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド - Google Patents

癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド Download PDF

Info

Publication number
JP7550864B2
JP7550864B2 JP2022541692A JP2022541692A JP7550864B2 JP 7550864 B2 JP7550864 B2 JP 7550864B2 JP 2022541692 A JP2022541692 A JP 2022541692A JP 2022541692 A JP2022541692 A JP 2022541692A JP 7550864 B2 JP7550864 B2 JP 7550864B2
Authority
JP
Japan
Prior art keywords
pharma
cancer
acceptable salt
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022541692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510736A5 (https=
JP2023510736A (ja
Inventor
ワン，タオ
マイケル スコラ，ポール
ジャン，ジョンシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023510736A publication Critical patent/JP2023510736A/ja
Publication of JP2023510736A5 publication Critical patent/JP2023510736A5/ja
Application granted granted Critical
Publication of JP7550864B2 publication Critical patent/JP7550864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022541692A 2020-01-06 2020-11-19 癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド Active JP7550864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957373P 2020-01-06 2020-01-06
US62/957,373 2020-01-06
PCT/US2020/061172 WO2021141682A1 (en) 2020-01-06 2020-11-19 Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases

Publications (3)

Publication Number Publication Date
JP2023510736A JP2023510736A (ja) 2023-03-15
JP2023510736A5 JP2023510736A5 (https=) 2023-10-02
JP7550864B2 true JP7550864B2 (ja) 2024-09-13

Family

ID=73835779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541692A Active JP7550864B2 (ja) 2020-01-06 2020-11-19 癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド

Country Status (7)

Country Link
US (1) US20230063238A1 (https=)
EP (1) EP4087849B1 (https=)
JP (1) JP7550864B2 (https=)
KR (1) KR20220122751A (https=)
CN (1) CN114929714B (https=)
ES (1) ES2971704T3 (https=)
WO (1) WO2021141682A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087857B1 (en) 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US20230374073A1 (en) * 2020-10-08 2023-11-23 Bristol-Myers Squibb Company Dimeric milla immunomodulators
KR20230084211A (ko) * 2020-10-09 2023-06-12 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
JP2024544009A (ja) * 2021-12-03 2024-11-26 ブリストル－マイヤーズ スクイブ カンパニー 大員環免疫調節剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519062A (ja) 2013-03-15 2016-06-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１／ｐｄ−ｌ１およびｃｄ８０（ｂ７−１）／ｐｄ−ｌ１タンパク質／タンパク質相互作用の大環状阻害剤
JP2017536330A (ja) 2014-09-11 2017-12-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１／ｐｄ−ｌ１およびｃｄ８０（ｂ７−１）／ｐｄ−ｌ１タンパク質／タンパク質相互作用の大環状阻害剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519062A (ja) 2013-03-15 2016-06-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１／ｐｄ−ｌ１およびｃｄ８０（ｂ７−１）／ｐｄ−ｌ１タンパク質／タンパク質相互作用の大環状阻害剤
JP2017536330A (ja) 2014-09-11 2017-12-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１／ｐｄ−ｌ１およびｃｄ８０（ｂ７−１）／ｐｄ−ｌ１タンパク質／タンパク質相互作用の大環状阻害剤

Also Published As

Publication number Publication date
WO2021141682A1 (en) 2021-07-15
EP4087849B1 (en) 2023-12-27
JP2023510736A (ja) 2023-03-15
KR20220122751A (ko) 2022-09-02
CN114929714B (zh) 2024-05-31
CN114929714A (zh) 2022-08-19
ES2971704T3 (es) 2024-06-06
US20230063238A1 (en) 2023-03-02
EP4087849A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP7550864B2 (ja) 癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド
EP4087857B1 (en) Immunomodulators
JP2023503050A (ja) 免疫モジュレーター
JP2023517736A (ja) 免疫調節剤
JP2023500834A (ja) 免疫調整剤
EP4146670A1 (en) Immunomodulators
EP4225774B1 (en) Macrocyclic immunomodulators
EP4126902B1 (en) Immunomodulators
EP4225775B1 (en) Dimeric milla immunomodulators
JP2024516369A (ja) 環状ペプチド免疫調節剤
JP2023544730A (ja) 大環状ペプチドボロネート免疫調節剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240903

R150 Certificate of patent or registration of utility model

Ref document number: 7550864

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150